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Abstract 
Background: Low serum chloride is common in patients with chronic heart failure (CHF) 
and is associated with worse outcomes.  
Objectives: We investigated the clinical and prognostic associations, including cause of 
death associations, of low serum chloride in patients referred to a secondary care clinic with 
suspected heart failure. 
Methods: Patients with echocardiogram and serum chloride were evaluated (n=5613). CHF 
was defined as signs and symptoms of the disease and either left ventricular systolic 
dysfunction (LVSD) worse than mild: heart failure with reduced ejection fraction (HFREF) 
or LVSD mild or better and raised NTproBNP levels (>125 ng/L): heart failure with 
preserved ejection fraction (HFPEF).  Hypochloraemia was defined as greater than 2 standard 
deviations below the mean in the local normal distribution (<96 mmol/L). 
Results: Of the 5613 patients referred, 908 patients did not have CHF, 1988 had HFREF, and 
2717 had HFPEF. Compared to patients in Q4 (median chloride 106 mmol/L), patients in Q1 
(median 96 mmol/L) had more severe symptoms (38% NYHA III or IV vs. 25%, P<0.001) 
and were more likely to take loop diuretics (79% vs. 59%, P<0.001). The annual mortality 
rate for patients with CHF was 11%. Hypochloraemia was associated with an increased risk 
of death independent of NTproBNP. Patients in Q1 had a 2-fold increased risk of death 
compared to patients in Q4 (P<0.001). Sudden death was a common mode of death amongst 
patients with hypochloraemia. 
Conclusions: Hypochloraemia is strongly related to an adverse prognosis and may be a 
therapeutic target in patients with CHF. 
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Main text 
Introduction 
Electrolyte abnormalities are common in patients with chronic heart failure (CHF) and may 
affect treatment decisions and outcome. Hyponatraemia and both hypo- and hyper-kalaemia 
are adverse prognostic markers that have been therapeutic targets in some recent trials.1,2 
Hyponatraemia is a marker of severe CHF that might prompt consideration of a heart 
transplant.3 Until very recently, the possible importance of serum chloride levels in patients 
with CHF had been overlooked.   
Hypochloraemia (<96 mmol/L) is common in patients with CHF and is associated with a 
higher risk of mortality in patients with acute or chronic heart failure, independent of 
prognostic markers such as amino-terminal pro-B-type natriuretic peptide (NTproBNP).4-10 It 
is not yet clear whether hypochloraemia has a direct pathological effect,5,8 or is merely a 
consequence of diuretic therapy,11 or a marker of congestion and disease severity.12 
Previous studies of chloride in patients with heart failure have either involved patients 
admitted with acute heart failure4 or myocardial infarction10, or highly selected study 
populations.5-7,9 Information on  the clinical and prognostic significance of abnormal serum 
chloride levels in unselected out-patients with heart failure, with either reduced (HFREF) or 
preserved ejection fraction (HFPEF) are lacking. Importantly, there is little data on the mode 
of death associated with abnormal chloride levels in patients with heart failure. We therefore 
investigated the prevalence and clinical and outcome associations of hyper- and 
hypochloraemia in a large cohort of ambulatory patients with HFREF or HFPEF.  
 
Methods 
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Patient population 
Between September 2000 and October 2016, consecutive referrals (n=6897) from both 
primary and secondary care were enrolled at a single secondary care clinic serving a local 
population of about 500,000 people (The Hull LifeLab). The study conforms to the principles 
outlined in the Declaration of Helsinki and was approved by relevant ethical bodies. All 
subjects gave their written informed consent. 
 
For the purpose of this analysis, CHF was defined as the presence of signs or symptoms 
consistent with the diagnosis and either left ventricular systolic dysfunction (LVSD) worse 
than mild, defined as HFREF or LVSD absent or at most mild and abnormal NT-pro-BNP 
plasma levels (>125 ng/L), defined as HFPEF.  
Hypochloraemia, hyponatraemia and hypokalaemia were defined as greater than 2 standard 
deviations below the mean electrolyte level in the normal distribution for the local population 
(<96 mmol/L, <135 mmol/L and <3.5 mmol/L respectively). Hyperchloraemia was defined 
as greater than two standard deviations above the mean chloride level in the normal 
distribution for the local population (>105 mmol/L).  
 
Outcomes 
Patients were followed up until 16/10/2016. The primary outcomes of interest were all-cause 
mortality and the composite endpoint of mortality or hospitalisation with heart failure. For 
each patient who died, the cause of death was adjudicated as detailed in the supplement. 
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Statistical Analysis 
Categorical data are presented as percentages, normally distributed continuous data are 
presented as mean + standard deviation (SD) and non-normally distributed variables are 
presented as median and interquartile range (IQR). 
The relationship between chloride and other variables was assessed by Pearson correlation 
coefficients. Uni- and multi- variable linear regression models were used to identify variables 
associated with serum chloride. Only variables with p<0.05 in univariable analysis were 
included in the multivariable model. Log-transformed NTproBNP was used.  
Patients with CHF were sub-divided as a whole and by phenotype (HFREF or HFPEF) into 
chloride quartiles and groups depending on the presence of hyponatraemia and / or 
hypochloraemia: group 1 – hyponatraemia and hypochloraemia, group 2 – normal sodium 
and hypochloraemia, group 3 – hyponatraemia and normal chloride and group 4 – normal 
sodium and chloride levels.  Chi-squared tests were used to compare categorical variables and 
one-way analysis of variance (ANOVA) to compare continuous variables across the groups, 
assumptions of ANOVA (normality or residuals and equal variance) were checked. Kruskal-
Wallis tests were used to compare non-normally distributed continuous variables across the 
quartiles and groups.  
Associations between variables and outcome were assessed with Cox regression, 
proportionality of hazards was checked by residual plotting. Univariable analysis was 
conducted using all variables in the dataset and variables with P>0.1 in univariable analysis 
or with more than 10% missing values (an arbitrary threshold) were not included in the 
multivariable analyses. Kaplan-Meier curves were used to demonstrate outcome by different 
groups.  
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Harrell’s C-statistic (area under the receiver-operating characteristic curve) was used to 
highlight the discrimination of different outcome models with and without chloride. 25-fold 
cross validation was performed on all variables in the database. 
Statistical analysis was carried out using the Stata 14 and SPSS 23 software packages. The 
two-tailed level of statistical significance was set at P < 0.05. 
 
Results 
Of the 6897 patients referred to the heart failure service, 5613 had data on echocardiography, 
NTproBNP and serum chloride at baseline, 908 patients did not have HF and were not 
included in the analysis. Of the remaining 4705 patients (table 1), 1988 patients had HFREF 
(supplementary table 1) and 2717 patients had HFPEF (supplementary table 2).  
The prevalence of hypochloraemia was 10.7% in patients with heart failure, 12.6 % in 
patients with HFREF and 9.3% in patients with HFPEF (P<0.001).  
By comparison, the prevalence of hyponatraemia was 11.3% amongst all patients with heart 
failure, 13.1% in patients with HFREF and 10.1% in patients with HFPEF (P=0.002).  
The prevalence of dual hypochloraemia and hyponatraemia was 5.9% in all patients, 7.2% in 
patients with HFREF and 5.0% in patients with HFPEF (P=0.001). 
The prevalence of hyperchloraemia was 13.2% amongst all patients with heart failure, 11.7%  
in patients with HFREF and 14.3% patients with HFPEF (P=0.001).  
 
Patient characteristics by serum chloride levels 
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Median chloride of patients in the first quartile (Q1) was 96 mmol/L (range 76-99 mmol/L) 
and 106 mmol/L (range 104-117 mmol/L) in the fourth quartile (Q4).  
Patients in Q1(including those with hypochloraemia (<96 mmol/L)) were older, more likely 
to have AF or diabetes and had more severe symptoms and a higher rate of loop diuretic 
prescription compared to patients in Q2-4 (P<0.001) (table 1). 59% of patients in Q1 who 
were taking loop diuretic were prescribed doses greater than 80mg of furosemide per day 
(table 1).  
Patients with hypochloraemia had higher NTproBNP than those with normal chloride levels 
(P<0.001). There was a general trend towards higher NTproBNP amongst patients in Q1 
compared to Q2-4; the relationship was significant (P<0.001) but weak (r2 = 0.021; 
scatterplot not shown).  
By contrast, patients with hyperchloraemia (>105 mmol/L) were less likely to have severe 
symptoms and signs, had lower NTproBNP and had a lower rate of diuretic prescription than 
patients with hypochloraemia or low-normal chloride (Q1 and Q2) (P<0.001). 
Similar trends were observed across the quartiles in the HFREF and HFPEF subgroups 
(supplementary tables 1 and 2).  Median NTproBNP was higher (1750 ng/L vs. 734 ng/L; 
P<0.001), and the proportion of patients with NYHA III or IV symptoms (35% vs. 24%; 
P<0.001) or taking a loop diuretic (75% vs. 54%; P<0.001) was greater amongst patients with 
HeFREF compared to patients with HFPEF. Additionally, the proportion of patients with 
hypochloraemia who were taking a loop diuretic was higher in patients with HFREF 
compared to patients with HFPEF (91% vs. 69%; P<0.001).  
 
Patient characteristics by serum chloride and sodium concentrations 
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Patients with hypochloraemia and either low (group 1) or normal (group 2) sodium had 
similar demographics and disease severity (table 2).  
However, there were several biochemical differences between the two groups possibly 
identifying two distinct groups of patients with hypochloraemia. For example, patients with 
hypochloraemia and normal sodium had higher bicarbonate, haemoglobin, haematocrit and 
rate of hypokalaemia than patients with hypochloraemia and hyponatraemia (P<0.001) (table 
2). Haemoglobin and haematocrit were similar in those with hyponatraemia regardless of 
chloride levels (group 1 and 3) (table 2).  
Disease severity, NTproBNP and rate of high dose diuretic prescription were lower in 
patients with normal chloride levels regardless of sodium levels (group 3 and 4) compared to 
those with low chloride levels regardless of sodium levels (group 1 and 2) (table 2) 
(P<0.001).  
 
 
 
Associations with serum chloride 
In all patients with heart failure and in both the HFREF and HFPEF subgroups, there was a 
strong positive correlation between chloride and sodium and a strong negative correlation 
with bicarbonate in multivariable analysis (supplementary figure 1). In all patients with heart 
failure and in both the HFREF and HFPEF subgroups, chloride had a weak negative 
correlation with log[NTproBNP] in univariable analysis. However, log[NTproBNP] was only 
associated with chloride after adjustment for other variables amongst patients with HFREF 
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(supplementary figure 1); the association was of borderline significance (correlation co-
efficient β = -0.326; t-statistic = -2.81; p=0.05). The strength and direction of other 
associations with serum chloride were similar between heart failure phenotypes. 
 
 
Predictors of outcome 
During a median follow up of 1691 days (IQR 754-1825), 1643 patients died and there were 
919 hospitalisations with heart failure. A total of 1946 patients either died or were 
hospitalised with heart failure.  
Low serum chloride was strongly and independently associated with increasing mortality 
(figure 1) and all-cause mortality or heart failure hospitalisation in all patients with heart 
failure and in the HFREF and HFPEF subgroups.  
Other independent predictors of all-cause mortality (ACM) or ACM or hospitalisation with 
heart failure in both HFREF and HFPEF were increasing age, increasing heart rate, severe 
symptoms (NYHA III or IV), loop diuretic use, increasing log[NTproBNP], increasing urea 
and decreasing albumin. No variable was an independent predictor of one endpoint but not 
the other.  
Variables that were independent predictors of outcome in patients with HFPEF and not 
HFREF were male sex, decreasing haemoglobin and increasing potassium levels. Variables 
that were independent predictors of outcome in patients with HFREF and not HFPEF were 
increasing bilirubin and the presence of ischaemic heart disease (IHD) (data not shown). 
However, neither haemoglobin, potassium, bilirubin or the presence of IHD were associated 
with outcome in all patients with heart failure (supplementary tables 5 and 6).. 
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Chloride as a predictor of adverse outcome 
With each unitary decrease in chloride, there was a 4% increase in mortality (hazard ratio 
(HR) = 1.04 (95% confidence interval (CI) = 1.02 – 1.06, P<0.001) and a 3% increase 
mortality or hospitalisation with heart failure (HR = 1.03 (95% CI = 1.02 – 1.05, P<0.001) 
independent of age, sex, body mass index, systolic blood pressure, heart rate, diabetes, IHD, 
NYHA class, log[NTproBNP], sodium, bicarbonate, calcium, potassium, haemoglobin, 
creatinine, urea, eGFR, albumin, alkaline phosphatase, alanine transferase, bilirubin, 
prescription of loop diuretics and CHF phenotype (HFREF vs. HFPEF) (supplementary table 
5 and 6). Patients in Q1 had around a 2 fold increased risk of mortality compared to patients 
in Q4 (figure 2). 
There was a tendency for mortality to increase as chloride increased substantially above the 
normal range (>105 mmol/L). However, there were very few patients with very high chloride 
levels and thus, the event rate was low. Patients in Q4 were at a slightly higher risk of adverse 
outcome compared to Q3, but the association was not statistically significant. 
Patients with hypochloraemia had a similar prognosis, regardless of whether sodium was low 
(group 1) or normal (group 2); and both groups had a markedly worse prognosis than patients 
with an isolated low sodium (group 3) or those with both a normal sodium and chloride 
(group 4) (figure 3). The unadjusted odds ratio for mortality for patients with hypochloraemia 
was 2.64 compared to 1.71 for patients with hyponatraemia.  
In 25-fold cross validation using all variables listed in table 1, chloride featured in 22 models 
(88%) as a predictor of outcome. By comparison, sodium, potassium, bicarbonate and 
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haemoglobin did not feature in any model. However, chloride did not add to the prognostic 
value of two models:  
1) Harrell’s C-statistic for a model including all variables that featured in >80% of cross 
validation models (age, sex, body mass index, atrial fibrillation, NYHA class, 
log[NTproBNP], chloride, urea, albumin, ALT, ALP and loop diuretic) was 0.742 without 
chloride and 0.748 with chloride.  
2) C-statistic for an a priori model of age, sex, creatinine, albumin, IHD, NTproBNP, NYHA 
class, and use of loop diuretics was 0.734 without chloride and 0.738 with chloride. 
 
Cause of death after 1 year follow up 
Amongst the 4505 patients with follow up data to one year, 11% died, 60% from 
cardiovascular causes (table 3). 
Death due to terminal heart failure was more common for patients in Q1 (including those 
with hypochloraemia) compared to Q2-4. Sudden death was more common in Q4 compared 
to Q1-3 but the event rate was much higher in Q1 (table 3).  
Similar trends were seen across the quartiles in the HFREF and HFPEF subgroups although 
mortality rate was higher in patients with HFREF compared to HFPEF (12% vs. 9%) and 
cardiovascular death was a more common mode of death amongst patients with HFREF 
compared to patients with HFPEF (69% vs. 52%) (supplementary table 4).  
Sudden death was more common among patients with hypochloraemia (groups 1 and 2) 
compared to those with normal chloride levels and hyponatraemia (group 3) (supplementary 
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table 3). The proportion of sudden deaths was greatest in patients with normal chloride and 
sodium levels (group 4) but the event rate was low. 
 
Discussion 
Our results add to the validity of findings of other studies:4-10 low serum chloride is 
associated with increased risk of morbidity and mortality in patients with heart failure 
regardless of phenotype and independent of more established prognostic variables such as 
NTproBNP or sodium.  
There are novel findings from the current study: 1) There may be an association between 
abnormal chloride levels and sudden death. 2) Hypochloraemia in patients with CHF might 
exist in two distinct biochemical phenotypes with implications for management. 3) Mortality 
risk increases substantially with chloride concentrations less than 100 mmol/L  
 
Chloride and NTproBNP 
Previous studies have either not included NTproBNP,7,10 found no difference,5,6,8,9 or found 
only a weakly significant difference4 in natriuretic peptides between patients with low and 
normal serum chloride concentrations. In a very large cohort, we found a significant but weak 
inverse relation between chloride and NT-proBNP: however, the two were not related when 
corrections were made for other variables.  
Hypochloraemia was an indicator of severe disease, regardless of heart failure phenotype, and 
both decreasing chloride and increasing NTproBNP were strong independent predictors of an 
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adverse outcome, suggesting that they are assessing different aspects of the heart failure 
syndrome. 
 
Chloride and sudden death 
Low serum chloride concentrations may have a stimulatory effect on a family of enzymes, 
with-no-lysine (WNK) kinases,13,14 which increase activity of Na+-K+-2Cl- (NKCC) and Na+-
Cl- (NC) co-transporters.15,16 NKCC and NC co-transporters have a role in maintaining 
myocyte volume and pH.17,18 Dysregulation of myocyte intracellular pH is arrhythmogenic,19 
and impairs contractility.20 Furthermore, cardiac chloride channels are implicated in sino-
atrial pacing ,21 and arrhythmogenesis.22 Thus, there are plausible mechanisms by which 
abnormal chloride levels might affect cardiac rhythm. However, how serum chloride affects 
the function of chloride channels or chloride-dependent co-transporters in humans is 
unknown. Further work is required.  
 
Chloride and sodium 
Hypochloraemia, regardless of sodium levels, was associated with higher risk of mortality 
and mortality or heart failure hospitalisation than isolated hyponatraemia. Sodium was not 
associated with adverse outcome after adjustment for other variables, including chloride. 
Monitoring serum sodium levels is recommended as an important prognostic marker in 
patients with heart failure, but it may be that chloride should have similar prominence in 
guidelines and clinical practice. 
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Our results support the assertions of Ferreira et al (2017) that chloride should be assessed in 
the context of serum sodium levels.10 There seem to be two biochemical phenotypes:  
1) In patients with hypochloraemia and hyponatraemia who have low haemoglobin, 
haematocrit and mean cell volume: in such patients, haemodilution may be an 
important contributor to the biochemical abnormalities.23,24 (Group 1 – table 2).  
2) In patients with hypochloraemia and normal sodium levels who have higher 
haemoglobin with higher bicarbonate and a higher rate of hypokalaemia: in such 
patients, the hypochloraemia may be due to depletion.11,25 (Group 2 – table 2). 
Metabolic alkalosis is the most common acid-base disturbance in patients with HF,26 and 
chloride depletion in the context of alkalosis is a well-recognised complication of diuretic 
treatment.26,27  
Both phenotypes have similar prevalence and risk of adverse outcome but the distinction may 
have implications for treatment, especially considering a similar proportion of patients have 
clinical signs of congestion in the two groups: while increasing the dose of loop diuretic 
might be appropriate to treat haemodilution, diuretic might also cause or worsen 
hypochloraemia. Patients with CHF who are prescribed loop diuretic have a poorer prognosis 
than those not needing diuretic treatment.28 Electrolyte abnormalities, such as 
hypochloraemia, may contribute to such findings.  
Acetazolamide, a carbonic anhydrase inhibitor that reduces bicarbonate and sodium re-
absorption and increases chloride re-absorption in the proximal tubule, can increase chloride 
levels whilst also having a diuretic action (a ‘chloride-sparing’ diuretic), and warrants further 
attention.29  
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It is important to note that not all patients with hypochloraemia were taking a loop diuretic, 
suggesting that other aspects of the heart failure syndrome, such as haemodilution, can cause 
hypochloraemia. This was particularly the case in the HFPEF subgroup; perhaps a reflection 
of the difficultly of making a clinical diagnosis of heart failure in patients with a normal 
ejection fraction, leading to a lower rate of diuretic prescription. 
Redefining the normal limits for serum chloride 
The U-shaped relation between chloride and mortality shows a substantial increase in risk of 
death at chloride concentrations less than 100 mmol/L (figure 1). Redefining hypochloraemia 
as <100 mmol/L would undoubtedly increase the number of patients who might be declared 
suitable for ‘chloride-sparing diuretics’ such as acetazolamide in future trials and clinical 
practice.  
We did find that very high levels of chloride were associated with an adverse outcome. 
However, the absolute number of patients at the high end of the chloride distribution was 
small and the absolute number of events smaller still, making it impossible to draw 
conclusions with certainty.  
 
Limitations 
The limitations of retrospective analyses apply to our study and confounding factors cannot 
be excluded. A substantial proportion of patients referred to our clinic was naïve to treatment; 
initiation or adjustments of current treatment might have led to improved electrolyte balance. 
Our data is a snapshot of a single time-point and no conclusions can be drawn on the 
importance of changing chloride levels over time. Data on urinary electrolyte concentrations 
is also missing which would be useful in further delineating the different phenotypes of 
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hypochloraemia. Some might not accept an NTproBNP > 125 pg/ml as diagnostic for heart 
failure with preserved ejection fraction, although it is consistent with recent European Society 
of Cardiology guidelines,30 diagnosis of HFPEF remains difficult in most cases.   
Although we recorded cause of death in a carefully prescribed manner, we were not able to 
use autopsy data to confirm mode and cause of deaths.    
 
Conclusion 
Hypochloraemia is an important adverse prognostic marker in patients with chronic heart 
failure and sudden death is a common mode of death amongst patients with heart failure and 
low chloride levels. Whether chloride is a target for treatment is not clear and should be 
tested in future clinical trials. 
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Figure legends 
Figure 1 
Title: Association between mortality and serum chloride in patients with heart failure 
Caption: Probability of all-cause mortality at 5-year follow up by serum chloride levels in 
patients with heart failure with a reduced ejection fraction or heart failure with a preserved 
ejection fraction. Frequency bars show the proportion of patients with a specific chloride 
concentration. The population was divided into quartiles based on serum chloride 
concentration, denoted by different coloured areas of the figure.    
 
Figure 2 
Title: Kaplan-Meier curve for quartiles of serum chloride 
Caption: Kaplan-Meier curves for all-cause mortality in patients with heart failure and a 
reduced ejection fraction or heart failure and a preserved ejection fraction divided by 
quartiles of serum chloride. Unadjusted hazard ratios for different quartiles compared to 
quartile 4 also included.  
Figure 3 
Title: Kaplan-Meier curve for groups based on the presence of hypochloraemia and/or 
hyponatraemia 
Caption: Kaplan-Meier curves for all-cause mortality in patients with heart failure and a 
reduced ejection fraction or heart failure and preserved ejection fraction divided by groups 
based on the presence of hypochloraemia and/or hyponatraemia. Group 1 – hypochloraemia 
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and hyponatraemia; group 2 – hypochloraemia and normal sodium levels; group 3 – normal 
chloride levels and hyponatraemia; group 4 – normal chloride and sodium levels. Unadjusted 
hazard ratios for different groups compared to group 4 also included.  
 
Supplementary figure 1 
Title: Univariable correlation matrix for variables associated with serum chloride levels in all 
patients with heart failure and in the HFREF or HFPEF subgroups. 
Caption: List of abbreviations used: ALP – alkaline phosphatase; ALT – alanine 
aminotransferase; BMI – body mass index; eGFR – estimate glomerular filtration rate; HF – 
heart failure; HFPEF – heart failure with preserved ejection fraction; HFREF – heart failure 
with reduced ejection fraction; HR – heart rate; LAD – left atrial diameter; LVEF – left 
ventricular ejection fraction; no. – number; NTproBNP – N-terminal B-type natriuretic 
peptide; SBP – systolic blood pressure. * P<0.05 on multivariable linear regression. ** 
P>0.05 on multivariable linear regression. Variables entered into the multivariable model for 
all patients included: age, BMI, sodium, potassium, bilirubin, haemoglobin, ALT, albumin, 
ALP, Urea, eGFR, bicarbonate, SBP, HR, log[NTproBNP]. Variables entered into the 
multivariable model for patients with HFREF included: age, BMI, sodium, potassium, 
bilirubin, haemoglobin, ALT, albumin, ALP, Urea, eGFR, bicarbonate, SBP, HR, 
log[NTproBNP]. Variables included in the multivariable model for patients with HFPEF 
included: age, BMI, sodium, potassium, bilirubin, haemoglobin, albumin, ALP, Urea, eGFR, 
bicarbonate, SBP, HR, log[NTproBNP].  
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Tables 
Table 1  
Patient characteristics by quartile of serum chloride in patients with heart failure. 
 
Variable Missing 
All patients  
N=4705 
Hypochloraemia 
<96 mmol/L 
N=503 
Q1 
N=1177 
Q2 
N=1176 
Q3 
N=1176 
Q4 
N=1176 
Hyperchloraemia 
>105 mmol/L 
N=622 
P for trend  
Chloride – (mmol/L) 0 
102  
(99 – 104) 
93 
(91-95) 
96 
(94-98) 
100 
(100-101) 
103 
(102-103) 
106 
(105-107) 
107 
(106-108) 
NA 
Demographics 
Age – years 0 73 (11) 74 (11) 74 (10) 73 (10) 71 (11) 72 (10) 73 (10) <0.001 
Sex (male) - no. (%) 0 2885 (61) 262 (52) 628 (53) 737 (63) 742 (63) 778 (66) 414 (67) <0.001 
SR – no. (%) 239 3129 (70) 311 (62) 725 (62) 769 (65) 819 (70) 816 (69) 440 (71) <0.001 
Diabetes - no. (%) 0 1152 (25) 146 (29) 339 (29) 306 (26) 22 (25) 252 (21) 126 (20) <0.001 
Hypertension - no. (%) 0 2006 (43) 198 (39) 477 (41) 496 (42) 511 (44) 522 (44) 277 (44) 0.26 
29 
 
IHD -- no. (%) 0 2306 (49) 227 (45) 525 (45) 566 (48) 604 (51) 611 (52) 343 (55) 0.001 
Signs and symptoms 
NYHA Class III/IV - no. (%) 230 1320 (29) 217 (44) 439 (38) 338 (30) 256 (22) 287 (25) 152 (25) <0.001 
Blood results 
NTproBNP – ng/L 0 
2408  
(397 – 2535) 
1817 
(722-4203) 
1476 
(604-3763) 
1040 
(422-2439) 
871 
(334-2000) 
873 
(333-2206) 
917 
(346- 2271) 
<0.001 
Haemoglobin – g/dL 315 
13.3  
(12.1 – 14.4) 
12.8 
(11.7-14.0) 
13.0 
(11.9-14.2) 
13.3 
(12.1-14.4) 
13.5 
(12.4-14.6) 
13.4 
(12.1-14.5) 
13.3 
(12.1-14.4) 
<0.001 
Haematocrit 280 
0.406  
(0.374 – 0.438) 
0.390 
(0.359-0.423) 
0.398 
(0.366-0.433) 
0.406 
(0.375-0.438) 
0.412 
(0.382-0.441) 
0.409 
(0.377-0.439) 
0.408 
(0.376-0.438) 
<0.001 
Sodium – mmol/L 7 
139  
(137 – 140) 
134 
(131-136) 
136 
(133-138) 
138 
(136-140) 
139 
(138-141) 
140 
(139-142) 
140 
(139-142) 
<0.001 
Hyponatraemia – no. (%) 7 533 (11) 279 (56) 407 (35) 100 (9) 20 (2) 6 (1) 3 (1)  
Potassium – mmol/L 38 
4.4  
(4.1-4.7) 
4.3 
(3.9-4.6) 
4.3 
(3.9-4.7) 
4.3 
(4.0-4.7) 
4.4 
(4.1-4.7) 
4.4 
(4.1-4.7) 
4.4 
(4.1-4.7) 
<0.001 
Hypokalaemia – no. (%) 38 143 (3) 49 84 27 22 10 4 <0.001 
30 
 
(9.7) (7.2) (2.3) (1.9) (0.9) (0.6) 
Bicarbonate – mmol/L 0 28 (26 – 30) 
30 
(28-32) 
30 
(28-32) 
29 
(27-30) 
28 
(26-30) 
27 
(25-28) 
26 
(25-28) 
<0.001 
eGFR – ml/min/1.73m2 152 
60  
(45 – 74) 
55 
(41-72) 
56 
(42-71) 
59 
(45-73) 
64 
(51-77) 
60 
(45-74) 
60.0 
(45.1-73.4) 
0.001 
Medications 
Loop diuretic- no. (%) 0 2965 (63) 403 (80) 935 (79) 805 (69) 580 (49) 645 (55) 279 (45) <0.001 
Furosemide Dose >80  mg/day – no. (%) 0 1212 (41) 246 (61) 549 (59) 322 (40) 175 (30) 166 (35) 75 (27) <0.001 
MRA- no. (%) 0 950 (20) 177 (35) 366 (31) 251 (21) 170 (15) 163 (14) 84 (14) <0.001 
ACE-I or ARB- no. (%) 0 3245 (69) 344 (68) 819 (70) 848 (72) 797 (68) 781 (66) 402 (65) 0.02 
BB - no. (%) 0 2741 (58) 235 (47) 613 (52) 698 (59) 713 (61) 717 (61) 378 (61) <0.001 
Echocardiography 
LVSD = severe - no. (%) 0 372 (8) 65 (13) 130 (11) 103 (9) 71 (6) 68 (6) 37 (6) <0.001 
 
Legend 
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ACE-I – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; BB – beta-blocker; BMI – body mass index;  eGFR – 
estimate glomerular filtration rate; no. – number; IHD – ischaemic heart disease; LVSD – left ventricular systolic dysfunction; MRA – 
mineralocorticoid receptor antagonist; NYHA – New York Heart Association; SR – sinus rhythm. 
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Table 2 
Patient characteristics by groups based on the presence of hypochloraemia and/or hyponatraemia 
 
Variable Missing 
Group 1 
N=279 
Group 2 
N=224 
Group 3 
N=254 
Group 4 
N=3942 
P 
Chloride – (mmol/L)  0 93 (90-94) 94 (93-95) 99 (97-100) 102 (100-104) <0.001 
Sodium – mmol/L 0 131 (129-133) 137 (135-139) 133 (132-134) 139 (138-141) <0.001 
Demographics 
Age – years  0 74 (11) 74 (10) 75 (10) 73 (11) 0.001 
Sex (male) - no. (%) 0 138 (50) 124 (55) 162 (64) 2456 (62) <0.001 
SR – no. (%) 204 186 (66) 128 (57) 175 (69) 2639 (67) 0.60 
Diabetes - no. (%) 0 82 (29) 64 (29) 83 (33) 923 (23) 0.001 
Hypertension - no. (%) 0 104 (37) 94 (42) 104 (41) 1701 (43) 0.26 
IHD -- no. (%) 0 133 (48) 94 (42) 126 (50) 1950 (50) 0.17 
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Symptoms 
NYHA Class III/IV - no. (%) 108 124 (45) 93 (43) 82 (33) 1018 (26)  
Blood results 
NTproBNP – ng/L  0 1816 (777-4298) 1805 (678-4143) 1193 (520-2591) 956 (371-2325) <0.001 
Haemoglobin – g/dL  243 12.5 (11.5-13.7) 13.2 (12.0-14.5) 12.5 (11.4-13.8) 13.4 (12.2-14.5) <0.001 
Haematocrit 273 
0.379 
(0.343-0.410) 
0.406 
(0.372-0.452) 
0.378 
(0.347-0.408) 
0.410 
(0.379-0.440) 
<0.001 
Potassium – mmol/L  29 4.4 (4.1-4.7) 4.0 (3.6-4.5) 4.5 (4.2-4.8) 4.4 (4.1-4.7) <0.001 
Hypokalaemia – no. (%)  29 8 (3) 41 (18) 3 (1) 90 (2) <0.001 
Bicarbonate – mmol/L  0 28 (27-30) 32 (30-35) 26 (25-27) 28 (26-30) <0.001 
eGFR – ml/min/1.73m2  128 58 (43-77) 52 (38-67) 59 (40-73) 61 (46-74) <0.001 
Medications 
Loop diuretic- no. (%) 0 207 (74) 196 (88) 167 (66) 2390 (61) <0.001 
Furosemide Dose >80  mg/day 0 119 (58) 127 (65) 66 (40) 897 (38)  
MRA- no. (%) 0 104 (37) 73 (33) 89 (35) 682 (17) <0.001 
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ACE-I or ARB- no. (%) 0 204 (73) 140 (63) 196 (77) 2701 (69) 0.002 
BB - no. (%) 0 135 (48) 100 (45) 160 (63) 2342 (59) <0.001 
Echocardiography 
Severe LVSD - no. (%)  41 (15) 24 (11) 16 (6) 291 (7) <0.001 
 
Legend 
ACE-I – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; BB – beta-blocker; BMI – body mass index;  eGFR – 
estimate glomerular filtration rate; no. – number; IHD – ischaemic heart disease; LVSD – left ventricular systolic dysfunction; MRA – 
mineralocorticoid receptor antagonist; NYHA – New York Heart Association; SR – sinus rhythm. 
Group 1 = Na <135mmol/L & Cl <96mmol/L 
Group 2 = Na >135mmol/L & Cl <96mmol/L 
Group 3 = Na <135mmol/L & Cl >96mmol/L 
Group 4 = Na >135mmol/L & Cl >96mmol/ 
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Table 3 
Mode of death in patients with heart failure and reduced ejection fraction or heart failure and a preserved ejection fraction by serum 
chloride quartile and hypo- and hyperchloraemia. 
 
 
 
All 
(N=4505) 
Quartile 1 
N=1128 
Quartile 2 
N=1118 
Quartile 3 
N=1121 
Quartile 4 
N=1138 
 Hypochloraemia 
(<96 mmol/L) 
N=483 
Chloride levels  
96-105 mmol/L 
N=3421 
Hyperchloraemia 
(>105 mmol/L) 
N=601 
Dead by 12m (All Cause) 481 204 110 78 89  119 312 50 
Annual mortality rate 11% 18% 10% 7% 8%  25% 9% 8% 
Cardiovascular (Primary) 291 (60) 126 (62) 58 (53) 43 (55) 64 (72)  68 (57) 184 (59) 39 (78) 
Terminal HF (Primary) 103 (21) 55 (27) 20 (18) 12 (15) 16 (18)  31 (26) 63 (20) 9 (18) 
Sudden Death (Primary) 154 (32) 64 (31) 26 (24) 26 (33) 38 (43)  35 (29) 96 (31) 23 (46) 
Non CV (Primary Cause) 169 (35) 72 (35) 47 (43) 29 (37) 21 (24)  47 (39) 113 (36) 9 (18) 
Unknown cause 21 (5) 6 (3) 5 (4) 6 (8) 4 (4)  4 (4) 15 (5) 2 (4) 
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Legend 
Total of patients with minimum FU of 1 year=4505. Figures in brackets are percentages of all deaths. List of abbreviations used: CV – 
cardiovascular; HF – Heart failure.  
 
 
 
 
 
 
 
Supplementary Table 1 
Patient characteristics by quartile of serum chloride in patients with heart failure and a reduced ejection fraction. 
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Variable Missing 
All HFREF 
N=1988 
Hypochloraemia 
N=251 
Q1 
N=497 
Q2 
N=497 
Q3 
N=497 
Q4 
N=497 
Hyperchloraemia 
N=233 
P for 
trend 
Chloride – (mmol/L) 0 
101 
(98-104) 
93 
(91-95) 
95 
(93-97) 
100 
(99-101) 
102 
(102-103) 
105 
(104-107 
107 
(106-108) 
n/a 
Demographics 
Age – years  0 71(11) 71 (11) 72 (11) 71 (11) 70 (12) 70 (11) 70 (11) 0.004 
Sex (male) - no. (%) 0 1485 (75) 165  (66) 337 (68) 364 (73) 390 (79) 394 (79) 185 (79) <0.001 
SR – no. (%) 118 1368 (69) 158 (63) 312 (63) 352 (71) 345 (69) 359 (72) 169 (73) 0.004 
Diabetes - no. (%) 0 472 (24) 86 (34) 151 (30) 132 (27) 98 (20) 91 (18) 41 (18) <0.001 
Hypertension - no. (%) 0 651 (33) 78 (31) 151 (30) 168 (34) 163 (33) 169 (34) 80 (34) 0.60 
IHD -- no. (%) 0 1278 (64) 150 (60) 297 (60) 32 (65) 327 (66) 332 (67) 154 (66) 0.01 
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Signs and symptoms 
NYHA Class III/IV - no. (%) 22 686 (35) 123 (50) 217 (44) 181 (37) 149 (30) 139 (29) 75 (33) <0.001 
Blood results 
NTproBNP – ng/L  0 
1750 
(750-3984) 
2731 
(1192-5848) 
2296 
(969-5250) 
1716 
(746-4014) 
1536 
(607-3077) 
1463 
(697-3601) 
1593 
(733-3844) 
<0.001 
Haemoglobin – g/dL  101 
13.5 
(12.2-14.6) 
13.0 
(11.9-14.1) 
13.1 
(12.0-14.2) 
13.5 
(12.2-14.5) 
13.7 
(12.4-14.9) 
13.6 
(12.5-14.6) 
13.5 
(12.5-14.7) 
<0.001 
Haematocrit 99 
0.411 
(0.379-0.443) 
0.394 
(0.362-0.429) 
0.400 
(0.370-0.437) 
0.410 
(0.379-0.441) 
0.421 
(0.390-0.449) 
0.417 
(0.384-0.445) 
0.419 
(0.386-0.444) 
<0.001 
Sodium – mmol/L  5 138 (136-140) 134 (131-136) 135 (133-138) 138 (136-140) 139 (138-141) 140 (139-142) 140 (139-142) <0.001 
Hyponatraemia – no. (%)  5 259 (13) 142 (57) 198 (36) 47 (9) 9 (2) 5 (1) 3 (1) <0.001 
Potassium – mmol/L  13 4.4 (4.1-4.7) 4.3 (3.9-4.6) 4.3 (4.0-4.7) 4.4 (4.1-4.7) 4.4 (4.2-4.7) 4.4 (4.1-4.7) 4.4 (4.1-4.8) 0.004 
39 
 
Hypokalaemia – no. (%) 13 58 (2.9) 28 (11.1) 38 (6.9) 10 (2.0) 5 (1.1) 5 (1.1) 7 (3.0) <0.001 
Bicarbonate – mmol/L  0 28 (26-30) 30 (28-32) 30 (28-32) 29 (27-31) 28 (27-30) 27 (25-28) 26 (25-28) <0.001 
eGFR – ml/min/1.73m2  76 59 (44-73) 55 (41-70) 54 (40-70) 58 (43-73) 62 (47-76) 60 (45-73) 60 (45-75) <0.001 
Medications 
Loop diuretic- no. (%) 0 1490 (75) 229 (91) 449 (90) 399 (80) 338 (68) 302 (61) 133 (57) <0.001 
Furosemide Dose >80  mg/day 0 689 (46) 148 (65) 279 (62) 204 (51) 114 (33) 92 (30) 41 (30) <0.001 
MRA- no. (%) 0 661 (33) 124 (49) 231 (47) 180 (36) 130 926) 120 (24) 57 (25) <0.001 
ACE-I or ARB- no. (%) 0 1614 (81) 198 (79) 402 (81) 405 (82) 407 (82) 400 (81) 186 (80) 0.94 
BB - no. (%) 0 1333 (67) 135 (54) 295 (59) 343 (69) 342 (69) 353 (71) 168 (72) <0.001 
Echocardiography 
Severe LVSD - no. (%) 0 372 (19) 65 (26) 100 (20) 130 (26) 67 (14) 75 (15) 37 (16) <0.001 
LAD – cm  281 4.4(0.8) 4.4 (0.8) 4.4 (0.8) 4.4 (0.8) 4.3 (0.8) 4.4 (0.7) 4.4 (0.7) 0.37 
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LVEF by Simpsons – %  796 32(8) 30 (8) 31 (9) 31 (7) 33 (7) 32 (8) 33 (8) 0.01 
 
Legend 
ACE-I – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; BB – beta-blocker; BMI – body mass index;  eGFR – 
estimate glomerular filtration rate; no. – number; HFREF – heart failure with a reduced ejection fraction; IHD – ischaemic heart disease; LVSD 
– left ventricular systolic dysfunction; MRA – mineralocorticoid receptor antagonist; NYHA – New York Heart Association; SR – sinus rhythm. 
 
 
Supplementary Table 2 
Patient characteristics by quartile of serum chloride in patients with heart failure and a preserved ejection fraction. 
 
Variable Missing All HFPEF Hypochloraemia Q1 Q2 Q3 Q4 Hyperchloraemia P for 
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N=2717 N=252 N=679 N=679 N=679 N=680 N=389 trend 
Chloride – (mmol/L)  0 
102 
(99-104) 
94 
(92-95) 
96 
(95-98) 
101 
(100-101) 
103 
(102-104) 
106 
(105-107) 
107 
(106-108) 
N/A 
Demographics 
Age – years  0 75 (10) 77 (9) 77 (9) 75 (10) 74 (10) 73 (10) 74 (9) <0.001 
Sex (male) - no. (%) 0 1400 (52) 97 (39) 269 (40) 373 (55) 362 (53) 397 (58) 229 (59) <0.001 
SR – no. (%) 86 1761 (65) 153 (61) 414 (61) 426 (63) 438 (65) 483 (71) 271 (70) 0.001 
Diabetes - no. (%) 0 680 (25) 60 (24) 182 (27) 186 (27) 165 (24) 147 (22) 85 (22) 0.06 
Hypertension - no. (%) 0 1355 (50) 120 (48) 345 (51) 330 (49) 338 (50) 342 (50) 197 (51) 0.87 
IHD -- no. (%) 0 1028 (38) 77 (31) 196 (29) 248 (37) 263 (39) 321 (47) 189 (49) <0.001 
Signs and symptoms 
NYHA Class III/IV - no. (%) 86 634 (24) 94 (39) 211 (32) 152 (23) 142 (21) 129 (19) 77 (20) <0.001 
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Blood results 
NTproBNP – ng/L  0 
734 
(289-1672) 
1175 
(549-2898) 
929 
(356-2192) 
672 
(287-1498) 
676 
(277-1551) 
634 
(263-1566) 
664  
(273-1644) 
<0.001 
Haemoglobin – g/dL  142 
13.2 
(12.0-14.3) 
12.6 
(11.5-13.9) 
13.0 
(11.9-14.1) 
13.2 
(12.1-14.3) 
13.2 
(12.1-14.3) 
13.3 
(12.1-14.4) 
13.1 (11.9-14.3) 0.18 
Haematocrit 181 
0.403 
(0.370-0.435) 
0.384 
(0.349-0.42) 
0.395 
(0.363-0.431) 
0.404 
(0.370-0.435) 
0.405 
(0.377-0.436) 
0.405 
(0.372-0.436) 
0.401 
(0.368-0.433) 
0.03 
Sodium – mmol/L  1 139 (137-141) 134 (131-136) 136 (134-138) 139 (137-140) 139 (138-141) 140 (139-142) 140 (139-142) <0.001 
Hyponatraemia – no. (%)  1 274 (10) 137 (54) 209 (34) 53 (8) 11 (2) 1 (0) 0 (0) <0.001 
Potassium – mmol/L  16 4.3 (4.0-4.6) 4.3 (3.9-4.6) 4.3 (3.9-4.6) 4.3 (4.0-4.6) 4.3 (4.1-4.6) 4.4 (4.1-4.7) 4.4 (4.1-4.7) <0.001 
Hypokalaemia – no. (%) 16 85 (3.1) 21 (8.3) 46 (6.8) 17 (2.5) 17 (2.5) 5 (0.7) 1 (0.3) <0.001 
Bicarbonate – mmol/L  0 28 (26-30) 30 (28-33) 30 (28-32) 28 (27-30) 28 (26-30) 27 (25-28) 26 (24-28) <0.001 
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eGFR – ml/min/1.73m2  52 61 (49-75) 55 (41-74) 58 (43-75) 61 (48-75) 62 (49-76) 61 (47-75) 60 (45-73) 0.01 
Medications 
Loop diuretic- no. (%) 0 1475 (54) 174 (69) 449 (66) 374 (55) 372 (55) 280 (41) 146 (38) <0.001 
Furosemide Dose >80  mg/day – no. (%) 0 523 (35) 98 (56) 236 (53) 125 (33) 98 (26) 64 (23) 34 (23) <0.001 
MRA- no. (%) 0 289 (11) 53 (21) 113 (17) 70 (10) 52 (8) 54 (8) 27 (7) <0.001 
ACE-I or ARB- no. (%) 0 1631 (60) 146 (58) 404 (60) 428 (63) 404 (60) 395 (58) 216 (56) 0.29 
BB - no. (%) 0 1408 (52) 100 (40) 306 (45) 343 (51) 387 (57) 372 (55) 210 (54) <0.001 
Echocardiography 
No LVSD - no. (%) 0 1652 (61) 169 (67) 467 (69) 420 (62) 38 (56) 382 (56) 236 (60) <0.001 
 
 
Legend 
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ACE-I – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; BB – beta-blocker; BMI – body mass index;  eGFR – 
estimate glomerular filtration rate; no. – number; HFPEF – heart failure with a preserved ejection fraction; IHD – ischaemic heart disease; LVSD 
– left ventricular systolic dysfunction; MRA – mineralocorticoid receptor antagonist; NYHA – New York Heart Association; SR – sinus rhythm. 
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Supplementary Table 3 
Mode of death in patients with heart failure and reduced ejection fraction or heart failure and a preserved ejection fraction by groups 
based on the presence of hypochloraemia and/or hyponatraemia. 
 
 
 
 
All 
(N=4502) 
Group 1 
N=265 
Group 
2 
N=218 
Group 3 
N=235 
Group 4 
N=3784 
Dead by 12m (All Cause) 481  70  49 32  330  
Annual mortality rate 11% 26% 22% 14% 9% 
Cardiovascular (Primary) 291 (60) 40 (57) 28 (57) 21 (65) 202 (61) 
Terminal HF (Primary) 103 (21) 17 (24) 14 (29) 11 (34) 61 (18) 
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Sudden Death (Primary) 154 (32) 22 (31) 13 (27) 6 (19) 113 (34) 
Non CV (Primary Cause) 169 27 20 9 113 
Unknown cause 21 3 1 2 15 
 
Legend 
Total of patients with minimum FU of 1 year=4502. 6 patients were excluded because they did not have sodium available Figures in brackets are 
percentage of all deaths. List of abbreviations used: CV – cardiovascular; HF – Heart failure. 
Group 1 = Na <135mmol/L & Cl <96mmol/L 
Group 2 = Na >135mmol/L & Cl <96mmol/L 
Group 3 = Na <135mmol/L & Cl >96mmol/L 
Group 4 = Na >135mmol/L & Cl >96mmol/L 
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Supplementary Table 4 
Mode of death in patients with heart failure by heart failure phenotype. 
Patients with HFREF with minimum follow up of 1 year (N = 1901) 
 
 
All 
(N=1901) 
Hypochloraemia 
(<96 mmol/L) 
N=240 
Quartile 
1 
N=533 
Quartile 
2 
N=494 
Quartile 
3 
N=445 
Quartile 
4 
N=429 
Hyperchloraemia 
(>105 mmol/L) 
N=224 
Dead by 12m (All Cause) 237  65 110 49 34 44 26 
Annual mortality rate - % 12 27 21 10 8 10 12 
Cardiovascular (Primary) 163 (69) 43 (66) 75 (68) 28 (57) 25 (73) 35 (80) 21 (81) 
Terminal HF (Primary) 64 (27) 22 (34) 35 (32) 13 (27) 6 (18) 10 (23) 4 (15) 
Sudden Death (Primary) 85 (36) 21 (32) 36 (33) 13 (27) 15 (44) 21 (48) 13 (50) 
Non CV (Primary Cause) 65 20 32 18 7 8 5 
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Unknown cause 9 2 3 3 2 1 0 
Patients with HFPEF with minimum follow up of 1 year (N = 2604) 
 
 
All 
(N=2604) 
Hypochloraemia 
(<96 mmol/L) 
N=243 
Quartile 
1 
N=595 
Quartile 
2 
N=624 
Quartile 
3 
N=676 
Quartile 
4 
N=709 
Hyperchloraemia 
(>105 mmol/L) 
N=377 
Dead by 12m (All Cause) 244 54 94 61 44 45 24 
Annual mortality rate - % 9 22 16 10 7 6 6 
Cardiovascular (Primary) 128 (52) 25 (46) 51 (54) 30 (49) 18 (41) 29 (64) 18 (75) 
Terminal HF (Primary) 38 (16) 9 (17) 20 (21) 7 (11) 6 (14) 6 (13) 5 (21) 
Sudden Death (Primary) 69 (28) 14 (26) 28 (30) 13 (21) 11 (25) 17 (38) 10 (42) 
Non CV (Primary Cause) 104 27 40 29 22 13 4 
Unknown cause 12 2 3 2 4 3 2 
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Legend 
Figures in brackets are percentages of all deaths. List of abbreviations used: HFREF – heart failure with a reduced ejection fraction; HFPEF – 
heart failure with a preserved ejection fraction; CV – cardiovascular; HF – Heart failure.  
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Supplementary Table 5 
Univariable and Multivariable analysis for all-cause mortality in all patients with heart failure 
 
Variable Univariable Multivariable 
HR X2 - Wald p HR X2 - Wald p 
Demographics 
Age – years  1.06 (1.05-
1.06) 
573 <0.001 1.05 (1.04-
1.05) 
251 <0.001 
Sex (male vs female) - no. (%) 1.13 (1.05-
1.23) 
9 0.002 1.30 (1.18-
1.45) 
25 <0.001 
BMI – kg/m2 0.97 (0.96-
0.98) 
65 <0.001    
SBP – mmHg 1.00 (0.99-
1.00) 
34 <0.001    
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HR – bpm  1.01 (1.00-
1.01) 
36 <0.001    
AF  (vs SR) 1.38 (1.27-
1.50) 
54 <0.001    
Diabetes (vs non-diabetic) 1.26 (1.15-
1.38) 
25 <0.001 1.12 (1.01-
1.25) 
5 0.033 
Hypertension  (vs non-hypertensive)  0.95 (0.88-
1.03) 
1 0.243    
IHD (vs no IHD) 1.16 (1.07-
1.25) 
13 <0.001    
Signs & Symptoms 
NYHA Class  (III/IV vs I/II)   1.99 (1.83-
2.16) 
261 <0.001 1.42 (1.29-
1.57) 
53 <0.001 
Peripheral oedema  (>ankles vs none or trace)  1.84 (1.68-
2.02) 
176 <0.001    
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Lung crackles (present vs absent)  1.93 (1.73-
2.16) 
141 <0.001    
JVP (raised vs not raised) 1.92 (1.72-
2.16) 
125 <0.001    
Bloods 
Log(NTproBNP) – ng/L  2.79 (2.60-
3.00) 
757 <0.001 1.47 (1.33-
1.63) 
53 <0.001 
Haemoglobin – g/dL  0.81 (0.80-
0.83) 
288 <0.001    
Sodium – mmol/L  0.94 (0.93-
0.95) 
124 <0.001    
Chloride – mmol/L 0.94 (0.93-
0.95) 
207 <0.001 0.96 (0.94-
0.98) 
17 <0.001 
Calcium – mmol/L  0.14 (0.10-
0.18) 
180 <0.001    
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Potassium – mmol/L  1.10 (1.00-
1.18) 
4 0.045    
Bicarbonate – mmol/L  1.01 (1.00-
1.03) 
2 0.126    
Creatinine-umol/L 1.00 (1.00-
1.00) 
265 <0.001    
Urea - mmol/L  1.07 (1.06-
1.07) 
617 <0.001 1.03 (1.01-
1.04) 
15 <0.001 
eGFR – ml/min/1.73m2  0.98 (0.98-
0.98) 
461 <0.001    
Albumin – g/l  0.89 (0.89-
0.90) 
451 <0.001 0.95 (0.93-
0.96) 
58 <0.001 
Bilirubin – umol/L 1.02 (1.01-
1.02) 
34 <0.001    
ALP – iu/L  1.01 (1.01- 300 <0.001 1.00 (1.00- 47 <0.001 
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1.01) 1.00) 
ALT – iu/L  0.99 (0.99-
0.99) 
25 <0.001 0.99 (0.99-
1.00) 
18 <0.001 
Medications 
Loop diuretic (vs no loop diuretic) 2.00 (1.84-
2.18) 
244 <0.001 1.26 (1.14-
1.40) 
19 <0.001 
Furosemide Dose (>80mg day vs 1-79mg/day) 1.38 (1.26-
1.52) 
47 <0.001    
Echocardiography 
HFrEF vs HFpEF 1.29 (1.19-
1.39) 
40 <0.001    
LAD – cm  1.30 (1.24-
1.38) 
98 <0.001    
LVEF by Simpsons – %  0.99 (0.98-
0.99) 
57 <0.001    
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Supplementary Table 5 – Univariable and Multivariable analysis for all-cause mortality in all patients with heart failure 
Legend 
Only variables associated with outcome in univariable analysis (p<0.1) were entered in multivariable models. Variables with >10% missing 
values were excluded. Variables that were non-significant in multivariable analysis were not recorded. Variables included in multivariable 
model: age, sex, BMI, SBP, HR, diabetes, IHD, NYHA class; log(NT-pro-BNP), sodium, calcium, potassium, haemoglobin, chloride, creatinine, 
urea, eGFR, albumin, ALP, ALT, bilirubin, loop diuretics, HFrEF, HFpEF. 
 
HF – heart failure; HFrEF – heart failure with reduced ejection fraction; HFpEF – heart failure with preserved ejection fraction; no. – number; 
BMI – body mass index; SBP – systolic blood pressure; HR – heart rate; SR – sinus rhythm; IHD – ischaemic heart disease; NYHA – New York 
Heart Association; JVP – jugular venous pulse; eGFR – estimate glomerular filtration rate; LAD – left atrial diameter; LVEF – left ventricular 
ejection fraction 
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Supplementary table 6 
Univariable and Multivariable analysis for all-cause mortality or heart failure hospitalisation in all patients with heart failure 
 
 
Variable Univariable Multivariable 
HR X2 - Wald P HR X2 - Wald p 
Demographics 
Age – years  1.05 (1.04-
1.05) 
434 <0.001 1.04 (1.03-
1.04) 
159 <0.001 
Sex (male vs female) - no. (%) 1.14 (1.05-
1.23) 
10 0.001 1.25 (1.13-
1.38) 
20 <0.001 
BMI – kg/m2 0.98 (0.97-
0.99) 
40 <0.001    
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SBP – mmHg 1.00 (0.99-
1.00) 
51 <0.001    
HR – bpm  1.01 (1.01-
1.01) 
50 <0.001    
AF  (vs SR) 1.39 (1.28-
1.50) 
60 <0.001    
Diabetes (vs non-diabetic) 1.28 (1.17-
1.40) 
31 <0.001 1.12 (1.01-
1.24) 
5 0.027 
Hypertension  (vs non-hypertensive)  1.01 (0.94-
1.09) 
0 0.833    
IHD (vs no IHD) 1.17 (1.09-
1.26) 
17 <0.001    
Signs & Symptoms 
NYHA Class  (III/IV vs I/II)   2.02 (1.87-
2.19) 
300 <0.001 1.40 (1.28-
1.53) 
53 <0.001 
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Peripheral oedema  (>ankles vs none or trace)  1.98 (1.79-
2.20) 
164 <0.001    
Lung crackles (present vs absent)  1.99 (1.79-
2.21) 
161 <0.001    
JVP (raised vs not raised) 1.94 (1.74-
2.17) 
139 <0.001    
Bloods 
Log(NTproBNP) – ng/L  2.90 (2.71-
3.11) 
893 <0.001 1.63 (1.47-
1.80) 
92 <0.001 
Haemoglobin – g/dL  0.82 (0.80-
0.84) 
294 <0.001    
Sodium – mmol/L  0.94 (0.93-
0.95) 
111 <0.001    
Chloride – mmol/L 0.94 (0.93-
0.95) 
208 <0.001 0.97 (0.95-
0.98) 
14 <0.001 
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Calcium – mmol/L  0.16 (0.12-
0.21) 
166 <0.001    
Potassium – mmol/L  1.07 (0.99-
1.16) 
3 0.081    
Bicarbonate – mmol/L  1.01 (1.00-
1.03) 
4 0.038    
Creatinine-umol/L 1.00 (1.00-
1.00) 
246 <0.001    
Urea - mmol/L  1.06 (1.06-
1.07) 
565 <0.001 1.02 (1.01-
1.03) 
9 0.003 
eGFR – ml/min/1.73m2  0.98 (0.98-
0.98) 
441 <0.001    
Albumin – g/l  0.90 (0.90-
0.91) 
394 <0.001 0.96 (0.95-
0.97) 
33 <0.001 
Bilirubin – umol/L 1.02 (1.01- 48 <0.001    
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1.03) 
ALP – iu/L  1.01 (1.01-
1.01) 
290 <0.001 1.00 (1.00-
1.00) 
38 <0.001 
ALT – iu/L  0.99 (0.99-
1.00) 
12 <0.001 1.00 (0.99-
1.00) 
9 0.003 
Medications 
Loop diuretic (vs no loop diuretic) 2.15 (1.98-
2.34) 
324 <0.001 1.37 (1.24-
1.51) 
37 <0.001 
Furosemide Dose (>80mg day vs 1-79mg/day) 1.38 (1.26-
1.51) 
51 <0.001    
Echocardiography 
HFrEF vs HFpEF 1.46 (1.35-
1.57) 
98 <0.001    
LAD – cm  1.35 (1.29-
1.42) 
140 <0.001    
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LVEF by Simpsons – %  0.98 (0.98-
0.99) 
103 <0.001    
 
Legend 
Only variables associated with outcome in univariable analysis (p<0.1) were entered in multivariable models. Variables with >10% missing 
values were excluded. Variables that were non-significant in multivariable analysis were not recorded. Variables included in multivariable 
model: age, sex, BMI, SBP, HR, diabetes, IHD, NYHA class; log(NT-pro-BNP), sodium, calcium, potassium, bicarbonate, haemoglobin, 
chloride, creatinine, urea, eGFR, albumin, ALP, ALT, bilirubin, loop diuretics, HFREF, HFPEF. 
 
HF – heart failure; HFREF – heart failure with reduced ejection fraction; HFPEF – heart failure with preserved ejection fraction; no. – number; 
BMI – body mass index; SBP – systolic blood pressure; HR – heart rate; SR – sinus rhythm; IHD – ischaemic heart disease; NYHA – New York 
Heart Association; JVP – jugular venous pulse; eGFR – estimate glomerular filtration rate; LAD – left atrial diameter; LVEF – left ventricular 
ejection fraction 
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Table 1  
Patient characteristics by quartile of serum chloride in patients with heart failure. 
 
Variable Missing 
All patients  
N=4705 
Hypochloraemia 
<96 mmol/L 
N=503 
Q1 
N=1177 
Q2 
N=1176 
Q3 
N=1176 
Q4 
N=1176 
Hyperchloraemia 
>105 mmol/L 
N=622 
P for trend  
Chloride – (mmol/L) 0 
102  
(99 – 104) 
93 
(91-95) 
96 
(94-98) 
100 
(100-101) 
103 
(102-103) 
106 
(105-107) 
107 
(106-108) 
NA 
Demographics 
Age – years 0 73 (11) 74 (11) 74 (10) 73 (10) 71 (11) 72 (10) 73 (10) <0.001 
Sex (male) - no. (%) 0 2885 (61) 262 (52) 628 (53) 737 (63) 742 (63) 778 (66) 414 (67) <0.001 
SR – no. (%) 239 3129 (70) 311 (62) 725 (62) 769 (65) 819 (70) 816 (69) 440 (71) <0.001 
Diabetes - no. (%) 0 1152 (25) 146 (29) 339 (29) 306 (26) 22 (25) 252 (21) 126 (20) <0.001 
Hypertension - no. (%) 0 2006 (43) 198 (39) 477 (41) 496 (42) 511 (44) 522 (44) 277 (44) 0.26 
IHD -- no. (%) 0 2306 (49) 227 (45) 525 (45) 566 (48) 604 (51) 611 (52) 343 (55) 0.001 
Signs and symptoms 
NYHA Class III/IV - no. (%) 230 1320 (29) 217 (44) 439 (38) 338 (30) 256 (22) 287 (25) 152 (25) <0.001 
Blood results 
NTproBNP – ng/L 0 
2408  
(397 – 2535) 
1817 
(722-4203) 
1476 
(604-3763) 
1040 
(422-2439) 
871 
(334-2000) 
873 
(333-2206) 
917 
(346- 2271) 
<0.001 
Haemoglobin – g/dL 315 
13.3  
(12.1 – 14.4) 
12.8 
(11.7-14.0) 
13.0 
(11.9-14.2) 
13.3 
(12.1-14.4) 
13.5 
(12.4-14.6) 
13.4 
(12.1-14.5) 
13.3 
(12.1-14.4) 
<0.001 
Haematocrit 280 
0.406  
(0.374 – 0.438) 
0.390 
(0.359-0.423) 
0.398 
(0.366-0.433) 
0.406 
(0.375-0.438) 
0.412 
(0.382-0.441) 
0.409 
(0.377-0.439) 
0.408 
(0.376-0.438) 
<0.001 
Sodium – mmol/L 7 
139  
(137 – 140) 
134 
(131-136) 
136 
(133-138) 
138 
(136-140) 
139 
(138-141) 
140 
(139-142) 
140 
(139-142) 
<0.001 
Hyponatraemia – no. (%) 7 533 (11) 279 (56) 407 (35) 100 (9) 20 (2) 6 (1) 3 (1)  
Potassium – mmol/L 38 
4.4  
(4.1-4.7) 
4.3 
(3.9-4.6) 
4.3 
(3.9-4.7) 
4.3 
(4.0-4.7) 
4.4 
(4.1-4.7) 
4.4 
(4.1-4.7) 
4.4 
(4.1-4.7) 
<0.001 
Hypokalaemia – no. (%) 38 143 (3) 
49 
(9.7) 
84 
(7.2) 
27 
(2.3) 
22 
(1.9) 
10 
(0.9) 
4 
(0.6) 
<0.001 
Bicarbonate – mmol/L 0 28 (26 – 30) 
30 
(28-32) 
30 
(28-32) 
29 
(27-30) 
28 
(26-30) 
27 
(25-28) 
26 
(25-28) 
<0.001 
eGFR – ml/min/1.73m2 152 
60  
(45 – 74) 
55 
(41-72) 
56 
(42-71) 
59 
(45-73) 
64 
(51-77) 
60 
(45-74) 
60.0 
(45.1-73.4) 
0.001 
Medications 
Loop diuretic- no. (%) 0 2965 (63) 403 (80) 935 (79) 805 (69) 580 (49) 645 (55) 279 (45) <0.001 
Furosemide Dose >80  mg/day – no. (%) 0 1212 (41) 246 (61) 549 (59) 322 (40) 175 (30) 166 (35) 75 (27) <0.001 
MRA- no. (%) 0 950 (20) 177 (35) 366 (31) 251 (21) 170 (15) 163 (14) 84 (14) <0.001 
ACE-I or ARB- no. (%) 0 3245 (69) 344 (68) 819 (70) 848 (72) 797 (68) 781 (66) 402 (65) 0.02 
BB - no. (%) 0 2741 (58) 235 (47) 613 (52) 698 (59) 713 (61) 717 (61) 378 (61) <0.001 
Echocardiography 
LVSD = severe - no. (%) 0 372 (8) 65 (13) 130 (11) 103 (9) 71 (6) 68 (6) 37 (6) <0.001 
 
Legend 
ACE-I – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; BB – beta-blocker; BMI – body mass index;  eGFR – 
estimate glomerular filtration rate; no. – number; IHD – ischaemic heart disease; LVSD – left ventricular systolic dysfunction; MRA – 
mineralocorticoid receptor antagonist; NYHA – New York Heart Association; SR – sinus rhythm. 
 
